We are excited to announce with Taiho Pharmaceutical and Cullinan Therapeutics the presentation of new positive results from the pivotal Phase 2b cohorts of the REZILIENT1 trial, a Phase 1/2 clinical trial. For more information, please visit: https://lnkd.in/e8M_uZgd #NSCLC #ASCO2025
